揭示了一种不常见的并发症:皮奥格利塔使用后的肺溢液
Ranjana Chimauriya1, Abhinandan Chittal2, Khalid Malik2
1MedStar Health Georgetown University (Baltimore) Internal Medicine Residency Program, USA.
概括
皮奥格利塔是一种糖尿病药物,很少会在没有心力衰竭的情况下导致肺部液体积聚 (肺部溢液). 在这种情况下,停止药物治疗解决了输液.
科学领域:
- 内分泌学 在内分泌学.
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮奥格利塔是一种PPAR-γ激动剂,用于治疗2型糖尿病.
- 已知的副作用包括胀和水分保留.
- 隔离性多叶膜溢出是一种罕见的不良反应.
研究的目的:
- 报告一个罕见的与pioglitazone相关的复发性胸腔溢出病例.
- 突出认识到药物诱导的多叶膜溢出的重要性.
主要方法:
- 一个60多岁的女性患有2型糖尿病的病例报告.
- 详细的临床观察和药物史.
- 在停止服用皮奥格利塔后,评估输出溶液的解决方案.
主要成果:
- 患者出现了复发的左侧膜溢出.
- 在停止服用皮奥格利塔后,液消失了.
- 没有发现心力衰竭的证据.
结论:
- 皮奥格利塔可以诱导胸腔溢出,即使没有心力衰竭.
- 早期诊断和戒药对于管理这种罕见的不良影响至关重要.
- 这一案例补充了关于皮奥格利塔诱导的多流的有限文献.
相关概念视频
Pleural Effusion II: Symptoms and Management
943
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
943
Pleural Effusion I: Introduction
5.0K
Pleural effusion is an abnormal fluid accumulation in the pleural cavity, a narrow space between the lungs and the chest wall. It is not a disease per se but rather a symptom or indication of an underlying disease. In normal circumstances, this space contains a small amount of fluid (5 to 15 mL), a lubricant facilitating the non-frictional movement of the pleural surfaces.
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
There are two main types of pleural effusion: transudative and exudative. They are differentiated using Light's...
5.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones
762
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
762
Dipeptidyl Peptidase 4 Inhibitors
814
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
814
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
1.2K
Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...
1.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
558
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
558


